| 2006 |
Thurid Buch, geb. Fassbender |
The (European) Public Assessment Report as an extended part of the European application procedure - Regulatory background and practical considerations |
|
|
| 2006 |
Dr. Sabine Drechsler |
The re-evaluation regulatory assessment procedure for old herbal medicinal products in Germany, focussing on clinical aspects |
|
|
| 2006 |
Monika Frei |
Parallel import of generic medicinal products - Possible impacts of the Kohlpharma Case |
|
|
| 2006 |
Dr. Hans-Joachim Gamperl |
Drug Risk Management from an Industry Perspective - a Task for the Life Time of a Medicinal Product |
|
|
| 2006 |
Ellen Güttler |
Extended Role of Scientific Advice as a Consequence of the New Medicines Legislation in the EU including a Comparison to the Situation in the USA |
|
|
| 2006 |
Claudia Hahne |
Angemessenheit der Regelungen zum Vertrieb von Medizinprodukten |
|
|
| 2006 |
Dr. Maria Hambrügge |
Effective drug regulation as a promoter for access to medicinal products in developing countries New initiatives within the legal framework in the EU and regulatory activities by WHO and regional regulatory harmonisation initiatives |
|
|
| 2006 |
Sylvaine Hartmann |
Change Control and Variations in Chemistry Consequences on the regulatory workload for Active Substance Manufacturers |
|
|
| 2006 |
Dr. Katrin Jahn |
Zulassung und Handel von Produkten der traditionellen chinesischen Medizin (TCM) in der Schweiz und in Europa unter besonderer Berücksichtigung von Österreich und Deutschland |
|
|
| 2006 |
Dr. Silke Jung |
New drug substances with abuse potential: Points to consider for the development and marketing |
|
|
| 2006 |
Dr. Sibylle Kaiser |
Tissue engineered products Need and requirements for an appropriate harmonised EU regulatory framework |
|
|
| 2006 |
Dr. Cortina Kaletta |
Overview of the Regulatory Environment for Developing New Vaccines Including the Specific Smallpox Vaccine and Pandemic Influenza Virus Vaccines |
|
|
| 2006 |
Anette Keiser |
Preparation of a check list to perform GMP-Audits of contract manufacturers following relevant provisions of law. |
|
|
| 2006 |
Anne Louise Kirkegaard |
Strategic ordination of the regulatory instruments for obtaining early market access in the EEA, USA and Canada of a novel anticancer drug |
|
|
| 2006 |
Dr. Angelika Koch |
Möglichkeiten und Grenzen der Vermarktung von pflanzlichen Produkten |
|
|
| 2006 |
Dr. Manfred Kurz |
Registration of antibody based medicinal products |
|
|
| 2006 |
Dr. Katrin Mayer |
Maintenance / life cycle management of a MRP-product A case study |
|
|
| 2006 |
Dr. Roger Müller-Pfaff |
Einführung des Hämaphereseverfahrens in den Blutspendedienst der Bundeswehr |
|
|
| 2006 |
Kristina Mumber |
Regulatory Environment for medicinal products in Russian Federation |
|
|
| 2006 |
Dr. Christiane Pering |
„Regulatory framework for the marketing authorisation of medicinal products for human use containing or consisting of genetically modified organisms – comparison of requirements in Europe and the United States“ |
|
|
